Børge Sørvoll
Finanzdirektor/CFO bei ARCTICZYMES TECHNOLOGIES ASA
Vermögen: 223 185 $ am 30.04.2024
Profil
Børge Sørvoll is currently the Chairman of Biotec BetaGlucans AS and the Chief Financial Officer of ArcticZymes Technologies ASA. Previously, he worked as the Managing Director & Chief Financial Officer of Troms Kraft Invest AS, the Chief Financial Officer of Front Exploration AS, and a Manager at Subsea 7 Norway AS.
He holds an MBA from the University of Wyoming.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
08.02.2024 | 95 428 ( 0,19% ) | 223 185 $ | 30.04.2024 |
Aktive Positionen von Børge Sørvoll
Unternehmen | Position | Beginn |
---|---|---|
ARCTICZYMES TECHNOLOGIES ASA | Finanzdirektor/CFO | 01.10.2014 |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Vorsitzender | - |
Ehemalige bekannte Positionen von Børge Sørvoll
Unternehmen | Position | Ende |
---|---|---|
Front Exploration AS
Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Finanzdirektor/CFO | - |
Subsea 7 Norway AS
Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Corporate Officer/Principal | - |
Troms Kraft Invest AS | Vorstandsvorsitzender | - |
Ausbildung von Børge Sørvoll
University of Wyoming | Masters Business Admin |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 1 |
---|---|
ARCTICZYMES TECHNOLOGIES ASA | Health Technology |
Private Unternehmen | 4 |
---|---|
Front Exploration AS
Front Exploration AS Contract DrillingIndustrial Services Front Exploration AS explores oil and gas and is ultimately controlled by the Government of Denmark. The company is based in Tromsø, Norway. Front Exploration was acquired by Ørsted A/S on June 27, 2012. | Industrial Services |
Subsea 7 Norway AS
Subsea 7 Norway AS Miscellaneous Commercial ServicesCommercial Services Part of Subsea 7 SA, Subsea 7 Norway AS is a Norwegian company that engages in general trading activities. The company is based in Stavanger, Norway. The CEOs are John Evans, Monica Th. Bjørkmann. The company was founded in 1985. | Commercial Services |
Troms Kraft Invest AS | |
Biotec BetaGlucans AS
Biotec BetaGlucans AS Pharmaceuticals: MajorHealth Technology Part of Lallemand, Inc., Biotec BetaGlucans AS is a Norwegian company that specializes in developing M-Gard®, an immunomodulator that enhances the body's defense mechanisms against pathogens. The company is based in Tromsø, Norway. The technology behind M-Gard® has been successfully developed for alternative indications and applications, including nutraceuticals, wound care, and immunotherapy. The CEO of the company is Jethro Holter. Biotec BetaGlucans was acquired by Danstar Ferment AG from ArcticZymes Technologies ASA on December 31, 2020 for $7.93 million. | Health Technology |